bevacizumab,atezolizumab,gemcitabine
roche
[]
 phii imbrave 151 #1l adv cholangio/gb cancer showing cis/gem/bev/atezo modest improvement in primary endpoint pfs (no formal hypothesis testing) w/orr 24.1 vs 25.3% and median os nr vs 11.4 mos compared to cis/gem as key secondary endpoints #gi23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope